Decreased Operating Expenses
Operating expenses for Q1 2025 were $5.8 million, an 11.4% decrease from $6.6 million in Q1 2024, driven by lower clinical research and administrative costs.
Significant Progress in Clinical Trials
Lisata has advanced its clinical development portfolio, particularly with its product candidate Certepetide, which showed promising preliminary results in various trials, including ASCEND and Bolster.
Improved Financial Position
Lisata reported a net loss of $4.7 million for Q1 2025, compared to $5.4 million in Q1 2024, indicating improved financial management.
Secured Special Regulatory Designations
Certepetide received multiple special designations from the FDA and EMA, enhancing its regulatory standing and potential market entry.
Positive Preliminary Cohort A Data
Preliminary data from the ASCEND trial showed a positive trend in overall survival and complete responses in the Certepetide-treated group.